Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program

by: Iola Bonggay

The Food and Drug Administration, otherwise referred to as FDA, is a federal government agency operating within the United States Department of Health and Human Services that is primarily responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs.

The grants and programs of the FDA are all geared towards the achievement of its primary agency mission which is to "protect consumers and enhance public health by maximizing compliance of FDA regulated products and minimizing risk associated with those products."

In this capacity, the Food and Drug Administration has recently established the Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program in an attempt to study the effects of various physicochemical properties of ophthalmic suspensions and emulsions on ocular bioavailability.

To this effect, the program will cover the key physicochemical properties which may impact clearance, distribution, and drug release; specifically globule/particle size distribution, surface change, osmolality, pH, viscosity, and dispersibility.

It is known that there are several kinds of opthalmic drugs which are available in the market today. The goal of this study is to determine which manufacturing differences may result in physicochemical differences which in turn may affect clearance, distribution, and release of the drug.

  (continued...)

Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
  Page 2

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Minority-Based Community Clinical Oncology Program Groups
In line with this mission, the National Institutes of Health has recently collaborated with the National Cancer Institute (NCI) in an attempt to establish the Minority-Based Community Clinical Oncology Program Groups (MBCCOP).

---

Small Business Innovation Research Phase IIB Bridge Awards
In line with this mission, the NIH has recently constituted the Small Business Innovation Research Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization Program.

---

Health Care Innovation Challenge
The Centers for Medicare and & Medicaid Services has recently established the Health Care Innovation Challenge in an attempt to solicit proposals to establish interesting new models of service delivery that can potentially deliver the three-part aim of better health, better health care, and finally, lower costs through the improved quality of Medicare, Medicaid, and Children's Health Insurance Program.

---

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---